---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-111586"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-08-27T23:59:59+00:00"
generated_at: "2026-05-17T09:52:33.665800+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MannKind receives $5M upfront from United Therapeutics for new product option exercise

## Summary
- MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.
- MannKind receives $5M upfront payment and is eligible for up to $35M in milestone payments.
- MannKind will manufacture clinical trial materials; United Therapeutics will conduct all other preclinical and clinical development.
- MannKind will earn 10% royalties on net sales of the additional product if approved.
- United Therapeutics exercised withdrawal option retains right to withdraw the exercise for the new agent.

## SEC filing metadata
- accession: 0000950170-25-111586
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-08-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017025111586/0000950170-25-111586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017025111586/mnkd-20250824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-111586
- JSON: https://secwatch.observer/filing/0000950170-25-111586.json
- Plain text: https://secwatch.observer/filing/0000950170-25-111586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.